Cas no 115290-81-8 (Destolyl Atomoxetine)
Destolyl Atomoxetine Chemical and Physical Properties
Names and Identifiers
-
- (R)-3-(Methylamino)-1-phenylpropanol
- (R)-(+)-3-(N-METHYLAMINO)-1-PHENYL-1-PROPANOL
- (1R)-3-(methylamino)-1-phenylpropan-1-ol
- Destolyl Atomoxetine
- AC-5330
- (1R)-(+)-3-(Methylamino)-1-phenylpropan-1-ol
- (3R)-N-Methyl-3-hydroxy-3-phenylpropylamine
- (R)-3-Hydroxy-N-methyl-3-phenylpropylamine
- (R)-N-Methyl-3-hydroxy-3-phenylpropylamine
- (R)-N-Methyl-3-phenyl-3-hydroxypropylamine
- Atomoxetine EP Impurity H
- AtoMoxetine Related CoMpound A
- Atomoxetine hydrochloride impurity H
- (R)-3-(Methylamino)-1-phenylpropan-1-ol
- (R)-3-Methylamino-1-phenyl-propan-1-ol
- AKOS015851057
- DB-001116
- XXSDCGNHLFVSET-SNVBAGLBSA-N
- AKOS006272678
- (R)-3-methylamino-1-phenyl-1-propanol
- EN300-141240
- F75914
- Benzenemethanol, alpha-[2-(methylamino)ethyl]-, (alphaR)-
- (3r)-methyl-3-hydroxy-3-phenylpropylamine
- SCHEMBL1201340
- starbld0019046
- 115290-81-8
- (r)-n-methyl-3-phenyl-3-hydroxy-propylamine
-
- MDL： MFCD00070087
- Inchi： 1S/C10H15NO/c1-11-8-7-10(12)9-5-3-2-4-6-9/h2-6,10-12H,7-8H2,1H3/t10-/m1/s1
- InChI Key： XXSDCGNHLFVSET-SNVBAGLBSA-N
- SMILES： O[C@@H](C1C=CC=CC=1)CCNC
Computed Properties
- Exact Mass: 165.11500
- Monoisotopic Mass: 165.115
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 12
- Rotatable Bond Count: 4
- Complexity: 110
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 32.3A^2
- XLogP3: 1
Experimental Properties
- Density: 1.017
- Melting Point: 64 °C
- Boiling Point: 286 oC
- Flash Point: 115 oC
- Refractive Index: 1.53
- PSA: 32.26000
- LogP: 1.72040
- Vapor Pressure: 0.0±0.6 mmHg at 25°C
Destolyl Atomoxetine Security Information
- Signal Word：warning
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
-
Warning Statement：
P264Thoroughly clean after treatment
P280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective mask
P305If it enters the eyes
P351Rinse carefully with water for a few minutes
P338Remove the contact lens(If any)And easy to operate,Continue flushing
P337If eye irritation persists
P313Obtain medical advice/care - Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
Destolyl Atomoxetine Customs Data
- HS CODE：2922199090
- Customs Data：
China Customs Code:
2922199090Overview:
2922199090. Other amino alcohols and their ethers,Esters and their salts(Except those containing more than one oxygen-containing group). VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%
Declaration elements:
Product Name, component content, use to, The color of ethanolamine and its salt should be reported, The package of ethanolamine and its salt shall be declared
Summary:
2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Destolyl Atomoxetine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D297510-2.5mg |
Destolyl Atomoxetine |
115290-81-8 | 2.5mg |
$167.00 | 2023-05-18 | ||
| TRC | D297510-25mg |
Destolyl Atomoxetine |
115290-81-8 | 25mg |
$ 800.00 | 2023-09-08 | ||
| eNovation Chemicals LLC | Y1092540-10g |
(R)-3-(methylamino)-1-phenylpropan-1-ol |
115290-81-8 | 95% | 10g |
$190 | 2024-07-28 | |
| eNovation Chemicals LLC | Y1092540-25g |
(R)-3-(methylamino)-1-phenylpropan-1-ol |
115290-81-8 | 95% | 25g |
$300 | 2024-07-28 | |
| Biosynth | QEA29081-5 mg |
Destolyl atomoxetine |
115290-81-8 | 5mg |
$155.95 | 2023-01-03 | ||
| Biosynth | QEA29081-10 mg |
Destolyl atomoxetine |
115290-81-8 | 10mg |
$249.50 | 2023-01-03 | ||
| Biosynth | QEA29081-25 mg |
Destolyl atomoxetine |
115290-81-8 | 25mg |
$467.75 | 2023-01-03 | ||
| Biosynth | QEA29081-50 mg |
Destolyl atomoxetine |
115290-81-8 | 50mg |
$748.50 | 2023-01-03 | ||
| Biosynth | QEA29081-100 mg |
Destolyl atomoxetine |
115290-81-8 | 100MG |
$1,198.00 | 2023-01-03 | ||
| Enamine | EN300-141240-0.05g |
(1R)-3-(methylamino)-1-phenylpropan-1-ol |
115290-81-8 | 0.05g |
$1032.0 | 2023-06-06 |
Destolyl Atomoxetine Related Literature
-
Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
-
Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
-
Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
Additional information on Destolyl Atomoxetine
Destolyl Atomoxetine: A Comprehensive Overview
Destolyl Atomoxetine, also known by its CAS number 115290-81-8, is a widely recognized compound in the field of pharmaceuticals. This compound has garnered significant attention due to its unique properties and applications in modern medicine. In this article, we will delve into the latest research findings, chemical characteristics, and therapeutic potentials of Destolyl Atomoxetine.
Atomoxetine, the active ingredient in Destolyl Atomoxetine, is a selective norepinephrine reuptake inhibitor (SNRI). It is primarily used in the treatment of attention deficit hyperactivity disorder (ADHD) and has shown promising results in managing symptoms associated with this condition. Recent studies have highlighted its efficacy in improving cognitive functions, particularly in individuals with ADHD, by modulating neurotransmitter activity in the brain.
The chemical structure of Destolyl Atomoxetine plays a pivotal role in its pharmacological activity. Its molecular formula, C17H23N3O, indicates a complex arrangement of atoms that contributes to its selective action on norepinephrine transporters. This selectivity ensures that Atomoxetine has fewer side effects compared to other medications used for similar purposes. Researchers have also explored the stereochemistry of Atomoxetine, revealing that its enantiomers exhibit different pharmacokinetic profiles, which could be exploited for future drug development.
One of the most recent advancements in the study of Destolyl Atomoxetine involves its use in combination therapies. Clinical trials have demonstrated that combining Atomoxetine with other medications can enhance its therapeutic effects while reducing adverse reactions. For instance, studies have shown that co-administration with certain antidepressants can synergistically improve mood regulation and cognitive performance in patients with ADHD and comorbid depression.
The pharmacokinetics of Destolyl Atomoxetine have been extensively studied to optimize dosing regimens. It is metabolized primarily through cytochrome P450 enzymes, particularly CYP2D6, which plays a critical role in its clearance from the body. This understanding has led to personalized treatment approaches, where dosages are tailored based on an individual's genetic makeup and enzyme activity levels.
In terms of safety, Destolyl Atomoxetine has been generally well-tolerated by patients. However, recent research has identified rare but serious side effects, including hepatotoxicity and increased blood pressure. These findings underscore the importance of regular monitoring during treatment and highlight the need for further investigation into long-term safety profiles.
Looking ahead, ongoing research is focused on expanding the therapeutic applications of Atomoxetine beyond ADHD. Preclinical studies suggest potential benefits in treating neurodegenerative disorders such as Alzheimer's disease by enhancing synaptic plasticity and neuroprotective mechanisms. Additionally, investigations into its effects on sleep patterns have revealed promising results, paving the way for its use as a sleep aid in certain patient populations.
In conclusion, Destolyl Atomoxetine (CAS 115290-81-8) remains a cornerstone in the treatment of ADHD due to its unique pharmacological properties and clinical efficacy. As research continues to uncover new insights into its mechanisms of action and potential applications, this compound is poised to play an even greater role in modern medicine.
115290-81-8 (Destolyl Atomoxetine) Related Products
- 733703-95-2(Benzenemethanol, a-[2-(dimethylamino)ethyl]-4-ethyl-)
- 5554-64-3(3-Dimethylamino-1-phenyl-1-propanol)
- 114133-37-8(Benzenemethanol, a-[2-(methylamino)ethyl]-, (aS)-)
- 130194-42-2((S)-3-Amino-1-phenyl-propan-1-ol)
- 5424-50-0(Benzenemethanol, a-[2-(dimethylamino)ethyl]-,hydrochloride (1:1))
- 58574-60-0(3-Dimethylamino-1-(4-methylphenyl)propanol)
- 13634-66-7(3-(Dimethylamino)-1-(naphthalen-2-yl)propan-1-ol)
- 42142-52-9(a-2-(Methylamino)ethylbenzyl Alcohol)
- 137999-85-0((1R)-3-(methylamino)-1-phenylpropan-1-ol hydrochloride)
- 14593-03-4(Benzenepropanaminium,N,N-diethyl-g-hydroxy-N-methyl-,iodide (1:1))
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
